AAW registers new drug Hemlibra to combat Haemophilia A in Kuwait

KUWAIT CITY, June 24: Ali Abdulwahab Al Mutawa Commercial Co. (AAW), one of Kuwait’s leading medical distribution companies and the distributor of Roche Pharmaceuticals today announced it has registered the drug Hemlibra to combat Haemophilia A with factor VIII inhibitors, with the Ministry of Health in Kuwait.

Approved by the US Food and Drug Administration (FDA) and the European Commission, Hemlibra was shown to substantially reduce bleeds in adults and children in two of the largest pivotal clinical studies for people with haemophilia “A”.

Hemlibra is a preventative treatment that can be administered by an injection of a ready-to-use solution under the skin once weekly. Patients who participated in the clinical studies reported improvement in painful swellings, joint pain and physical function such as pain with movement and difficulty walking far.

Haemophilia A is an inherited, serious disorder in which a person’s blood doesn’t clot properly, leading to

Hemlibra

uncontrolled and often spontaneous bleeding. People with haemophilia “A” can bleed frequently, especially into their joints or muscles. These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility and long-term joint damage.